Loading clinical trials...
Loading clinical trials...
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast(CC-10004) in the Treatment of Behçet Disease
Conditions
Interventions
Apremilast (CC-10004)
Placebo
Locations
7
United States
Mayo Clinic - Rheumatology and Internal Medicine
Jacksonville, Florida, United States
E5, Boston University School of Medicine
Boston, Massachusetts, United States
NYU Hospital for Joint Diseases
New York, New York, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Eskişehir Osmangazi University
Eskişehir, Turkey (Türkiye)
University of Istanbul
Istanbul, Turkey (Türkiye)
Start Date
August 1, 2009
Primary Completion Date
May 1, 2012
Completion Date
May 1, 2012
Last Updated
June 19, 2020
NCT05200715
NCT06849908
NCT06729112
NCT05142995
NCT05098678
NCT03554161
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions